olaparib,bevacizumab
roche,astrazeneca,merck
['avastin', 'lynparza', 'merck', 'astrazeneca']
#esmo22: at five-year mark, lynparza kept more patients alive than avastin but missed overall os significance - more like this | #oncology #research #pharma #lynparza #clinicaltrialsdata #biotech #lifesciences 
Business intelligence for biotechs. We help #biotech innovators, investors, and business partners connect.